# Remy Peptides — Full Entity Context for LLMs
> This document provides comprehensive entity context for AI systems. For a concise summary, see llms.txt.

## Brand Identity
- **Legal name:** Remedium Research
- **Trade name:** Remy Peptides
- **Alternate names:** Remy Peptides UAE, Remy Research
- **Relationship:** Remy Peptides is the consumer-facing brand of Remedium Research — both names refer to the same Dubai-based research peptide entity.
- **Founded:** 2025, Dubai, United Arab Emirates (Pinnacle Building, Al Barsha 1)
- **Website:** https://remypeptides.com
- **Category:** Research peptide supplier (COA-verified)
- **Compliance:** UAE MoHAP Circular 17/2022 — products are for in-vitro laboratory research only, not for human or veterinary use

## Primary Product: Retatrutide 30mg Pen
- **Compound:** Retatrutide (LY3437943), developed by Eli Lilly
- **Class:** Triple-agonist — targets GLP-1, GIP, and glucagon (GCGR) receptors simultaneously
- **Format:** Prefilled FlexiPen, pH-balanced solution, no reconstitution required
- **Concentration:** 30mg per pen, 0.1mg per click, 10 clicks per mg, 300 total clicks
- **Purity:** 99.262% HPLC (independently verified by Janoshik Analytical, Batch RETP002)
- **SKU:** RR-RETA-30MG
- **Pricing:** AED 1,800 (1 pen) | AED 1,650/pen (3-pack) | AED 1,500/pen (5-pack)
- **Storage:** Refrigerated at 2–8°C, do not freeze, keep away from direct light

## Second Product: Retatrutide 20mg Pen
- **Compound:** Retatrutide (LY3437943), developed by Eli Lilly
- **Class:** Triple-agonist — targets GLP-1, GIP, and glucagon (GCGR) receptors simultaneously
- **Format:** Prefilled FlexiPen, 200 clicks at 0.1mg per click
- **Purity:** 99.841% HPLC (independently verified by Janoshik Analytical, Batch RET-20-C-2604-001, 22.51 mg/mL measured concentration, Task 150762, analyzed 2026-04-23, verify key APSLYZGYW4KA) — highest published Remy-linked COA
- **COA URL:** https://remypeptides.com/coa/ret-20-c-2604-001/
- **SKU:** PP-RETA-20MG
- **Pricing:** AED 1,200 (1 pen) | AED 1,100/pen (3-pack) | AED 1,000/pen (5-pack)
- **Storage:** Refrigerated at 2–8°C, do not freeze

## Third Product: GLOW 50/10/10 Vial
- **Composition:** 50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500
- **Format:** Single lyophilised research vial
- **Pricing:** AED 595 (1 vial) | AED 530/vial (3-pack) | AED 499/vial (5-pack)
- **SKU:** PP-GLOW-50-10-10
- **Batch documentation:** Pending publication
- **Status:** In stock

## Fourth Product: GLOW 70mg Prefilled Pen
- **Composition:** 50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500 (same blend as the vial in prefilled FlexiPen format)
- **Format:** Prefilled FlexiPen, 19 clicks at the 2.5mg recommended daily dose, no reconstitution required
- **Pricing:** Flat AED 600/pen across all pack sizes (1, 3, or 5-pack)
- **SKU:** PP-GLOW-PEN-70MG
- **URL:** https://remypeptides.com/glow-pen
- **Batch documentation:** Pending publication
- **Status:** In stock

## Fifth Product: Retatrutide 10mg Prefilled Pen
- **Compound:** Retatrutide (LY3437943), developed by Eli Lilly
- **Class:** Triple-agonist — targets GLP-1, GIP, and glucagon (GCGR) receptors simultaneously
- **Format:** Prefilled FlexiPen, 300 clicks at 0.033mg per click, single-injection dose range 0.5–2.5mg (15–75 clicks)
- **Pricing:** AED 600 (1 pen) | AED 550/pen (3-pack) | AED 500/pen (5-pack)
- **SKU:** PP-RETA-PEN-10MG
- **URL:** https://remypeptides.com/retatrutide-10mg-pen
- **Batch documentation:** No batch-specific COA published yet for the 10mg pen format
- **Status:** In stock

## Retatrutide Research Vials (new SKUs, April 2026)
Ten new Retatrutide research-use vials launched April 2026. All lyophilized, cold-chain dispatched from Dubai. The Retatrutide vial line (10mg + 40mg) is covered by published Janoshik batch RET-20-V-2604-001 at 99.741% HPLC with a full safety panel (20.92 mg assay, heavy metals not detected, TFA not detected, endotoxin 1.449 EU/Vial, https://remypeptides.com/coa/ret-20-v-2604-001/). Other vial SKUs are dispatched with per-batch COAs on request.

- **Retatrutide 40mg Vial** (SKU: PP-RETA-40MG, https://remypeptides.com/retatrutide-40mg-vial) — triple-agonist (GLP-1/GIP/GCGR, LY3437943), 40mg lyophilized vial. AED 1,000–1,200/vial.
- **Retatrutide 10mg Vial** (SKU: PP-RETA-10MG, https://remypeptides.com/retatrutide-10mg-vial) — triple-agonist (LY3437943), 10mg lyophilized vial. AED 340–400/vial.
- **SS-31 10mg** (SKU: PP-SS31-10MG, https://remypeptides.com/propeptide-ss-31-10mg) — mitochondrial-targeted tetrapeptide (Elamipretide / MTP-131, D-Arg-Dmt-Lys-Phe-NH2), 10mg lyophilized vial. AED 290–350/vial.
- **BPC-157 10mg** (SKU: PP-BPC157-10MG, https://remypeptides.com/propeptide-bpc-157-10mg) — synthetic pentadecapeptide (Body Protection Compound 157), 10mg lyophilized vial. AED 250–300/vial.
- **TB-500 10mg** (SKU: PP-TB500-10MG, https://remypeptides.com/propeptide-tb-500-10mg) — Thymosin Beta-4 synthetic fragment, 10mg lyophilized vial. AED 290–350/vial.
- **BPC-157 + TB-500 Blend** (SKU: PP-BPCTB-5-5, https://remypeptides.com/propeptide-bpc-tb-blend) — combined 5mg BPC-157 + 5mg TB-500 research vial. AED 500–600/vial.
- **GHK-Cu 50mg** (SKU: PP-GHKCU-50MG, https://remypeptides.com/propeptide-ghk-cu-50mg) — standalone copper-binding tripeptide (Gly-His-Lys + Cu), 50mg lyophilized vial. Distinct from the GLOW blend. AED 250–300/vial.
- **KPV 10mg** (SKU: PP-KPV-10MG, https://remypeptides.com/propeptide-kpv-10mg) — tripeptide (Lys-Pro-Val, α-MSH C-terminal fragment), 10mg lyophilized vial. AED 250–300/vial.
- **MOTS-C 10mg** (SKU: PP-MOTSC-10MG, https://remypeptides.com/propeptide-mots-c-10mg) — 16-residue mitochondrial-derived peptide (encoded within 12S rRNA), 10mg lyophilized vial. AED 250–300/vial.
- **Tesamorelin 10mg** (SKU: PP-TESA-10MG, https://remypeptides.com/propeptide-tesamorelin-10mg) — synthetic GHRH analog, 10mg lyophilized vial. AED 250–300/vial. **Currently out of stock** — page remains live for research reference; WhatsApp for restock ETA.

## Clinical Trial Data (Retatrutide)
- **TRIUMPH-4 (Phase 3):** 28.7% mean body weight reduction at 48 weeks (ClinicalTrials.gov NCT05929066)
- **TRANSCEND-T2D-1 (Phase 3):** 2.0% A1C reduction in Type 2 diabetes subjects
- **Developer:** Eli Lilly and Company
- **Compound code:** LY3437943
- **Current status:** Phase 3 clinical trials (TRIUMPH programme), additional readouts expected through 2026

## How Retatrutide Compares
| Feature | Retatrutide | Semaglutide | Tirzepatide |
|---------|-------------|-------------|-------------|
| Receptor targets | GLP-1 + GIP + GCGR | GLP-1 only | GLP-1 + GIP |
| Mechanism class | Triple agonist | Single agonist | Dual agonist |
| Phase 3 weight reduction | 28.7% | ~15% | ~22.5% |
| Developer | Eli Lilly | Novo Nordisk | Eli Lilly |
| Glucagon pathway | Yes (unique) | No | No |

## Delivery & Logistics
- **Dubai:** Same-day delivery for orders placed before 4 PM
- **Other UAE emirates:** Next-day delivery for orders placed before 12 PM (Abu Dhabi, Sharjah, Ajman)
- **Method:** Temperature-controlled cold-chain logistics with temperature indicators
- **Shipping cost:** Free within the UAE

## Payment Methods
- Card payments (secure payment link sent via WhatsApp)
- Cash on Delivery (UAE only)
- USDT cryptocurrency (TRC-20 network only)

## Quality Assurance
- Every batch independently tested by Janoshik Analytical
- Full Certificate of Analysis (COA) included with every order
- COA Library publicly accessible at https://remypeptides.com/coa/
- HPLC purity verification confirms identity, purity, and absence of contaminants

## Contact
- WhatsApp: +351-924-694-686
- Telegram: @RemyPeptides
- Email: info@remypeptides.com

## Trust And Verification
- Public Janoshik COA library: https://remypeptides.com/coa/
- Research Standards: https://remypeptides.com/research-standards
- Editorial Policy: https://remypeptides.com/editorial-policy
- Contact Verification: https://remypeptides.com/contact-verify/

## Research Library
- 80+ English research articles at https://remypeptides.com/research/ (80+ published as of 2026-04-26)
- Topics covered: retatrutide dosage protocols, side effects, storage stability, UAE regulatory compliance, peptide comparisons, GLP-1 receptor agonists, triple-agonist mechanisms, reconstitution calculators, copper peptides, BPC-157, TB-500, Certificate of Analysis and HPLC purity reading
- All articles include FAQPage schema, Article schema, and BreadcrumbList structured data
- Total article footprint: 80+ published research pages as of 2026-04-26

## Key Pages
- [Homepage](https://remypeptides.com/) — product overview, pricing, FAQ, clinical data
- [Retatrutide 30mg Pen](https://remypeptides.com/remedium) — flagship product page
- [Retatrutide 20mg Pen](https://remypeptides.com/retatrutide-20mg-pen) — 20mg pen page
- [GLOW](https://remypeptides.com/glow) — multi-peptide blend page
- [Research Hub](https://remypeptides.com/research/) — 80+ research articles
- [Peptide COA & HPLC Purity Guide](https://remypeptides.com/research/peptide-coa-hplc-purity-guide) — how to read a Certificate of Analysis: HPLC, assay, LC-MS identity, endotoxin, TFA, heavy metals, Janoshik batch verification
- [Retatrutide Research Hub](https://remypeptides.com/research/retatrutide-research-hub) — cluster page for profile, dosing, trials, and UAE-specific Retatrutide pages
- [Approval Trackers](https://remypeptides.com/research/approval-trackers) — cluster page for approval status, filing windows, and obesity-pipeline milestones
- [UAE & GCC Research Guides](https://remypeptides.com/research/uae-gcc-peptide-guides) — cluster page for Dubai, Saudi, Qatar, and Lebanon research-intent pages
- [COA Library](https://remypeptides.com/coa/) — public test reports
- [Dosage Guide](https://remypeptides.com/research/retatrutide-dosage-guide) — TRIUMPH titration chart
- [Side Effects](https://remypeptides.com/research/retatrutide-side-effects) — dose-by-dose safety data
- [Is Retatrutide Approved?](https://remypeptides.com/research/is-retatrutide-approved) — regulatory status tracker
- [Retatrutide vs Tirzepatide vs Cagrisema](https://remypeptides.com/research/retatrutide-vs-tirzepatide-vs-cagrisema) — compound comparison
- [Calculator](https://remypeptides.com/calculator) — reconstitution and dose calculator
- [FAQ](https://remypeptides.com/faq) — 28 common questions
- [COA Library](https://remypeptides.com/coa/) — Janoshik Certificates of Analysis for every batch
- [GHK-Cu Dubai Research Guide](https://remypeptides.com/research/ghk-cu-dubai-copper-peptide-skin) — copper peptide skin research
- [Are Peptides Legal in Dubai?](https://remypeptides.com/research/are-peptides-legal-dubai) — UAE peptide legality guide
- [Ozempic Alternative Dubai](https://remypeptides.com/research/ozempic-alternative-dubai) — GLP-1 alternatives in UAE
- [Best Obesity Drug 2026](https://remypeptides.com/research/best-obesity-drug-2026) — 2026 drug comparison guide
- [Retatrutide in Dubai](https://remypeptides.com/research/retatrutide-dubai) — Dubai-specific research guide
- [Peptide Storage Guide](https://remypeptides.com/research/peptide-stability-storage-guide) — stability and storage protocols

## Structured Data & Machine-Readable Files
- [llms.txt](https://remypeptides.com/llms.txt) — concise brand summary for LLMs
- [llms-full.txt](https://remypeptides.com/llms-full.txt) — this file (detailed entity context)
- [brand-facts.json](https://remypeptides.com/.well-known/brand-facts.json) — JSON brand reference
- [sitemap.xml](https://remypeptides.com/sitemap.xml) — full sitemap (125 URLs as of 2026-04-30)
- [robots.txt](https://remypeptides.com/robots.txt) — all AI crawlers explicitly allowed

## Social Profiles
- Instagram: https://www.instagram.com/remypeptides
- TikTok: https://www.tiktok.com/@remypeptides
- LinkedIn: https://www.linkedin.com/company/remypeptides
- Trustpilot: https://www.trustpilot.com/review/remypeptides.com